Skip to content
DE

SetmelanotidePrescription peptide

Setmelanotide addresses particular disorders of the brain’s appetite pathway. Its relevance starts with the cause of the obesity, rather than the number on the scales.

What is Setmelanotide?

Setmelanotide is a melanocortin-4 receptor agonist used in specified forms of obesity. Its EMA indication concerns defined genetic or hypothalamic conditions rather than obesity in general. 1

How it works

It activates MC4R signalling involved in appetite regulation, downstream of pathways disrupted in some of these conditions. 1

Effects studied

Hunger and body weight

Studies assess hunger and weight outcomes in eligible condition-specific populations, including relevant genetic disorders. 1 2

Evidence: The result depends on the cause of obesity; it cannot be assumed to apply to common obesity.

What does the evidence show?

Condition-specific clinical trials and EMA indication

A signal that does not arrive

The brain normally receives information about energy stores and adjusts hunger in response. In some rare disorders, part of that communication fails. Setmelanotide stimulates the melanocortin-4 receptor, a downstream component of this system. That is why its mechanism is especially relevant when a particular upstream signal is missing.

The diagnosis comes first

The EMA indication includes specified POMC, PCSK1 and LEPR deficiencies, Bardet–Biedl syndrome and acquired hypothalamic obesity. These are distinct clinical situations with different eligibility criteria. They should not be replaced by the much broader descriptions “slow metabolism” or “difficulty losing weight”. 1

What improvement would mean

Reducing persistent hunger can matter alongside reducing weight. Studies in specific conditions help establish whether the underlying appetite pathway gives the medicine a suitable target. A response in one genetic diagnosis cannot establish benefit in every other cause of obesity.

The trade-off is still medical

Skin pigmentation changes, gastrointestinal symptoms and effects on mood or sexual arousal need to be considered during treatment. Specialist assessment brings the diagnosis, expected benefit and monitoring together. The mechanism helps explain the treatment, but appetite symptoms alone cannot establish eligibility.

Safety & status

Skin pigmentation, gastrointestinal symptoms, mood changes and sexual-arousal effects require attention under the product information. 1 3

Country and product status

EMA lists Imcivree for specified genetic and acquired hypothalamic forms of obesity; eligibility depends on the diagnosed condition.

Frequently asked questions

Is it an alternative for anyone seeking weight loss?

No. Eligibility is tied to specific diagnoses and product criteria. 1

Why does the genetic diagnosis matter?

Its target sits in an appetite pathway disrupted by particular disorders; that biological fit is part of the treatment rationale. 1

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. EMA · Imcivree overview European regulator · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
  2. Setmelanotide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
  3. Setmelanotide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.